- Home
- DXCM vs A Comparison
DXCM vs A Comparison
Compare DXCM & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | A |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.4B | 38.0B |
| IPO Year | 2005 | 1999 |
Fundamental Metrics
Financial Performance| Metric | DXCM | A |
|---|---|---|
| Price | $78.15 | $173.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 29 | 22 |
| Target Price | $96.46 | ★ $181.05 |
| AVG Volume (30 Days) | ★ 3.2M | 1.6M |
| Earning Date | 10-29-2026 | 11-23-2026 |
| Dividend Yield | N/A | ★ 0.59% |
| EPS Growth | ★ 47.18 | 3.16 |
| EPS | 1.15 | ★ 3.55 |
| Revenue | N/A | ★ $4,472,000,000.00 |
| Revenue This Year | $12.17 | $7.95 |
| Revenue Next Year | $10.78 | $6.41 |
| P/E Ratio | $67.62 | ★ $48.96 |
| Revenue Growth | N/A | ★ 6.43 |
| 52 Week Low | $54.11 | $108.35 |
| 52 Week High | $92.59 | $179.10 |
Technical Indicators
Market Signals| Indicator | DXCM | A |
|---|---|---|
| Relative Strength Index (RSI) | 33.28 | 56.16 |
| Support Level | $62.02 | $163.32 |
| Resistance Level | $79.03 | $177.05 |
| Average True Range (ATR) | 2.61 | 4.88 |
| MACD | -0.75 | -0.54 |
| Stochastic Oscillator | 11.73 | 57.86 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
About A Agilent Technologies Inc.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.